Comparative Pharmacology
Head-to-head clinical analysis: DIPHEN versus EVALOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHEN versus EVALOSE.
DIPHEN vs EVALOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors. It also exhibits anticholinergic, sedative, antiemetic, and local anesthetic effects.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
50 mg IV/IM every 4 hours as needed for nausea/vomiting; 25-50 mg PO every 4-6 hours as needed for nausea/vomiting or motion sickness; 25 mg PO 3-4 times daily for vertigo; 15.6-25 mg IM/IV for antiemetic in surgery; maximum 300 mg/day.
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
None Documented
None Documented
Clinical Note
moderateDiphenoxylate + Torasemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide."
Clinical Note
moderateDiphenoxylate + Etacrynic acid
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid."
Clinical Note
moderateDiphenoxylate + Furosemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide."
Clinical Note
moderateTerminal elimination half-life is 22–72 hours (mean 30–40 hours); increases with hepatic disease or enzyme inhibitors.
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for ~70% of eliminated drug; biliary/fecal excretion accounts for ~30%.
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine
Diphenoxylate + Bumetanide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide."